ライフサイエンスコーパス: neuropsychiatric symptom

1 l candidates in this group and memantine for neuropsychiatric symptoms.

2 autism, epilepsy, cognitive impairment, and neuropsychiatric symptoms.

3 Streptococcus (GAS) infections that lead to neuropsychiatric symptoms.

4 ia should include the presence and nature of neuropsychiatric symptoms.

5 es than were most other medications used for neuropsychiatric symptoms.

6 lain why many CNVs affect a similar range of neuropsychiatric symptoms.

7 nts and substantially improves cognitive and neuropsychiatric symptoms.

8 ia), lethargy, parkinsonism, dyskinesias and neuropsychiatric symptoms.

9 ike symptoms, hematologic abnormalities, and neuropsychiatric symptoms.

10 nfirmation will facilitate correlations with neuropsychiatric symptoms.

11 placebo (sham IVIG) in reducing severity of neuropsychiatric symptoms.

12 of normal behaviour, or deficits underlying neuropsychiatric symptoms.

13 9) experience post-acute COVID-19, including neuropsychiatric symptoms.

14 ency department with worsening cognitive and neuropsychiatric symptoms.

15 abilities characterized by a variable set of neuropsychiatric symptoms.

16 o specific brain circuits can cause specific neuropsychiatric symptoms.

17 he effects of different brain pathologies on neuropsychiatric symptoms.

18 s in Post-COVID participants with persistent neuropsychiatric symptoms.

19 uage abilities, functional independence, and neuropsychiatric symptoms.

20 y and treat TBI patients with immune-related neuropsychiatric symptoms.

21 rable to infection-related dementia risk and neuropsychiatric symptoms.

22 Nearly all patients also had evidence of neuropsychiatric symptoms.

23 spensings of prescription drugs for specific neuropsychiatric symptoms.

24 artment, and completed serial assessments of neuropsychiatric symptoms.

25 features, including cognitive impairment and neuropsychiatric symptoms.

26 irus disease 2019 (COVID-19) with persistent neuropsychiatric symptoms.

27 eived problems attributable to cognitive and neuropsychiatric symptoms.

28 diagnosis of complications in patients with neuropsychiatric symptoms.

29 n of regional 11C-PBB3 binding capacity with neuropsychiatric symptoms.

30 ementia severity, functional impairment, and neuropsychiatric symptoms.

31 between changes in cognition and changes in neuropsychiatric symptoms.

32 d FS properties, which may contribute to TSC neuropsychiatric symptoms.

33 use of human morbidity, frequently involving neuropsychiatric symptoms.

34 ording to the disease stage along with other neuropsychiatric symptoms.

35 they might contribute to a broad spectrum of neuropsychiatric symptoms.

36 ep-brain stimulation to alleviate a range of neuropsychiatric symptoms.

37 ic inventory assessed memory functioning and neuropsychiatric symptoms.

38 3 may serve as a target for the treatment of neuropsychiatric symptoms.

39 d with respect to behavioural, cognitive and neuropsychiatric symptoms.

40 s for gastrointestinal, musculoskeletal, and neuropsychiatric symptoms.

41 g NFL athletes are related to later onset of neuropsychiatric symptoms.

42 sk are unclear in people not ascertained for neuropsychiatric symptoms.

43 w to diagnose, monitor, and treat its varied neuropsychiatric symptoms.

44 with physical dependency and the presence of neuropsychiatric symptoms.

45 s consisted of 29 patients with mTBI without neuropsychiatric symptoms.

46 tterns were seen for two major posttraumatic neuropsychiatric symptoms.

47 logy of tinnitus and connect tinnitus to the neuropsychiatric symptoms.

48 may provide therapeutic targets for specific neuropsychiatric symptoms.

49 of neural network excitability and triggers neuropsychiatric symptoms.

50 ium-phosphate deposition and associated with neuropsychiatric symptoms.

51 e absence of any history of strokes or other neuropsychiatric symptoms.

52 ral circuitry contributes to these disparate neuropsychiatric symptoms.

53 inflammation after TBI in the development of neuropsychiatric symptoms, 2) highlight potential microg

54 exercise intervention significantly improved neuropsychiatric symptoms (-3.59, 95% CI -7.08 to -0.09)

55 Overall, 46.4% of mutation carriers had neuropsychiatric symptoms (51.6% C9orf72, 40.8% GRN, 46.

56 shared and distinct mechanisms that mediate neuropsychiatric symptoms across disorders, e.g. 22q11.2

57 Persistent neurological and neuropsychiatric symptoms affect a substantial fraction

58 One potential mechanism for increased neuropsychiatric symptoms after TBI is via inflammatory

59 MS results in motor, cognitive, and neuropsychiatric symptoms, all of which can occur indepe

60 As anxiety and depression are common neuropsychiatric symptoms among people with cognitive im

61 024 NASEM definition of LC with at least one neuropsychiatric symptom and 31 recovered controls compl

62 pearance of dopaminergic dysfunction-related neuropsychiatric symptoms and an overall worsening of co

63 ence of preoperative nonspecific somatic and neuropsychiatric symptoms and associated conditions was

64 Monitoring for neuropsychiatric symptoms and avoiding rechallenge are r

65 s with mild Alzheimer's disease and specific neuropsychiatric symptoms and behaviours measured by the

66 Behavioral symptoms (neuropsychiatric symptoms and bvFTD core clinical criter

67 ality of life, self and informant ratings of neuropsychiatric symptoms and executive function behavio

68 he perturbations that drive the emergence of neuropsychiatric symptoms and experiences.

69 mood in healthy individuals with subclinical neuropsychiatric symptoms and explored the underlying me

70 ball League (NFL) players with cognitive and neuropsychiatric symptoms and in asymptomatic men with n

71 o both the presence or absence of individual neuropsychiatric symptoms and individual domain scores (

72 used to investigate the associations between neuropsychiatric symptoms and mortality, controlling for

73 Secondary outcome measures were overall neuropsychiatric symptoms and mortality.

74 Nondepressed with other neuropsychiatric symptoms and NOSYMP groups exhibited no

75 but the association between early presenting neuropsychiatric symptoms and PCC is unknown.

76 nset of the early features, characterized by neuropsychiatric symptoms and seizures preceded by a med

77 at theta could be a possible physiomarker of neuropsychiatric symptoms and specifically of anxiety in

78 ury, autoimmune disorders, and infections to neuropsychiatric symptoms and suicidality is only beginn

79 ses caused by trinucleotide repeat expansion-neuropsychiatric symptoms and the phenomenon of genetic

80 performed to rule out medical causes of the neuropsychiatric symptoms and to ascertain whether any c

81 cognitive and functional performance, higher neuropsychiatric symptoms, and brain structural and conn

82 ed which combinations of personality traits, neuropsychiatric symptoms, and cognitive lifestyle (year

83 ed which combinations of personality traits, neuropsychiatric symptoms, and cognitive lifestyle (year

84 ogy with combinations of personality traits, neuropsychiatric symptoms, and cognitive lifestyle.

85 provide insight into the pathophysiology of neuropsychiatric symptoms, and contribute to monitoring

86 We aimed to examine changes in cognition, neuropsychiatric symptoms, and CSF viral control associa

87 ctivity also had worsening verbal memory and neuropsychiatric symptoms, and extensive bilateral mesia

88 are prediabetes and the metabolic syndrome, neuropsychiatric symptoms, and low dietary folate.

89 on psychiatric outcomes including agitation, neuropsychiatric symptoms, and medication use.

90 adults, their correlation with cognitive and neuropsychiatric symptoms, and the accuracy of dementia

91 The association between neuropsychiatric symptoms (anxiety, depression, and fati

92 ) and white matter lesions with longitudinal neuropsychiatric symptoms (apathy, anxiety, and depressi

93 Specific neuropsychiatric symptoms are associated with shorter su

94 Neuropsychiatric symptoms are common and disabling in Pa

95 Neuropsychiatric symptoms are common in acute SARS-CoV-2

96 Neuropsychiatric symptoms are common in Parkinson's dise

97 Neuropsychiatric symptoms are commonly associated with c

98 Cognitive impairment and neuropsychiatric symptoms are frequent in Parkinson's di

99 A variety of neuropsychiatric symptoms are highly prevalent in differ

100 systemic lupus erythematosus (SLE) patients, neuropsychiatric symptoms are highly prevalent, being ob

101 gastrointestinal symptoms, anaphylaxis, and neuropsychiatric symptoms are kept under control with co

102 nguishable from classic FTD or ALS, although neuropsychiatric symptoms are more prevalent and, for AL

103 decline, but the associated behavioural and neuropsychiatric symptoms are of equal importance in the

104 Neuropsychiatric symptoms are recognized to occur in a s

105 Previous trials only evaluated neuropsychiatric symptoms as a secondary and an overall

106 Together, these findings highlight certain neuropsychiatric symptoms as early manifestations of AD.

107 udy suggested a transient, modest benefit on neuropsychiatric symptoms as measured by the neuropsychi

108 inhibition are common and highly distressing neuropsychiatric symptoms associated with negative outco

109 ges in the degree of physical dependency and neuropsychiatric symptoms associated with recent admissi

110 ed both cognitive (simple reaction time) and neuropsychiatric symptoms at 1 day postinjury that resol

111 ged >/=70 years) individuals with or without neuropsychiatric symptoms at baseline.

112 Prevalence of neuropsychiatric symptoms, based on ratings on the NPI i

113 be considered in aPL-positive patients with neuropsychiatric symptoms, because use of antiaggregants

114 There were no differences in prevalence of neuropsychiatric symptoms between participants with Alzh

115 changes (LATE-NC) is associated with greater neuropsychiatric symptom burden, compared to either path

116 he relationship between diagnostic group and neuropsychiatric symptom burden.

117 mer's disease is not associated with greater neuropsychiatric symptom burden.

118 terase inhibitor drugs improve cognition and neuropsychiatric symptoms but the clinical response is u

119 Memantine also holds promise to treat neuropsychiatric symptoms, but more prospective trials a

120 owing data support a high prevalence of PASC neuropsychiatric symptoms, but the current literature is

121 te networks in SLE patients with and without neuropsychiatric symptoms by examining functional connec

122 rotocols to help caregivers manage patients' neuropsychiatric symptoms, caregiver distress, and palli

123 king; patient function, quality of life, and neuropsychiatric symptoms; caregiver burden and well-bei

124 lse Control disorders And the association of neuRopsychiatric symptoms, cognition and qUality of life

125 withdrawal symptoms) and clinical outcomes (neuropsychiatric symptoms, cognitive function, and quali

126 Preclinical mutation carriers exhibited neuropsychiatric symptoms compared with non-carriers tha

127 ention showed significantly worse outcome in neuropsychiatric symptoms compared with the group receiv

128 A syndrome of motoric and neuropsychiatric symptoms comprising various elements, i

129 Neuropsychiatric symptom criteria of apathy and disinhib

130 criteria use a combination of characteristic neuropsychiatric symptoms, CSF proteins 14-3-3, MRI, and

131 Neuropsychiatric symptoms, depressive symptoms in partic

132 examination of potential mechanisms driving neuropsychiatric symptom development after TBI.

133 itive and affective abnormalities resembling neuropsychiatric symptoms directly in the hippocampus, w

134 o=2.946), and any one clinically significant neuropsychiatric symptom (domain score >/=4, hazard rati

135 ion (hazard ratio=1.942), mildly symptomatic neuropsychiatric symptoms (domain score of 1-3, hazard r

136 evaluated the effect of citalopram on the 12 neuropsychiatric symptom domains assessed by the Neurops

137 hy, particularly with regard to arrhythmias, neuropsychiatric symptoms, dosing of dobutamine, and int

138 Recurrence rates of neuropsychiatric symptoms during the 1-year period were

139 urological, cognitive (i.e., brain fog), and neuropsychiatric symptoms (e.g., depression, anxiety), w

140 nding capacity is associated with late-onset neuropsychiatric symptoms following TBI, and a close cor

141 epilepsy, intellectual disability, and other neuropsychiatric symptoms, for which available treatment

142 clinical manifestations are acute attacks of neuropsychiatric symptoms frequently precipitated by dru

143 A total of 221 SLE patients with and without neuropsychiatric symptoms from two different sites were

144 living former NFL players with cognitive and neuropsychiatric symptoms had higher tau levels measured

145 symptom prevalence vary, but at least 1 PASC neuropsychiatric symptom has been reported in as many as

146 For patients in whom neuropsychiatric symptoms have been much improved or hav

147 Neuropsychiatric symptoms have been reported as a promin

148 ard ratio=1.448), and clinically significant neuropsychiatric symptoms (hazard ratio=1.951) were asso

149 characterize immune signatures predictive of neuropsychiatric symptoms, identify cell type-specific c

150 The authors evaluated whether other neuropsychiatric symptoms improve with citalopram treatm

151 ded to fully clarify the unique role of each neuropsychiatric symptom in relation to biomarkers of br

152 er cent of the participants did not have any neuropsychiatric symptom in the last month.

153 participants, 75% (n = 270) had exhibited a neuropsychiatric symptom in the past month (62% were cli

154 he absence of anti-MAP-2 was associated with neuropsychiatric symptoms in 19.7% of patients (P = 0.00

155 ositivity in both assays was associated with neuropsychiatric symptoms in 76.5% of patients, whereas

156 Neuropsychiatric symptoms in addition to schizophrenia,

157 ork localization of clinical, cognitive, and neuropsychiatric symptoms in Alzheimer's disease', by Te

158 llary tangle spreading and the occurrence of neuropsychiatric symptoms in Alzheimer's disease.

159 Dementia and MCI are associated with neuropsychiatric symptoms in clinical samples.

160 causal role in the development of neurologic/neuropsychiatric symptoms in COVID-19.

161 redicting decline in cognitive functions and neuropsychiatric symptoms in early stages.

162 or initiative and one of the most prevalent neuropsychiatric symptoms in individuals with Alzheimer

163 are the first population-based estimates for neuropsychiatric symptoms in MCI, indicating a high prev

164 ined the link between clinically significant neuropsychiatric symptoms in mild Alzheimer's dementia a

165 The treatment of specific neuropsychiatric symptoms in mild Alzheimer's dementia s

166 own about the population-based prevalence of neuropsychiatric symptoms in mild cognitive impairment (

167 onship between aggressive behavior and other neuropsychiatric symptoms in patients with Alzheimer's d

168 to define the recurrence or continuation of neuropsychiatric symptoms in patients with Alzheimer's d

169 increased prevalence and early emergence of neuropsychiatric symptoms in patients with dementia with

170 ac et al emphasized the burden of stroke and neuropsychiatric symptoms in patients with hereditary th

171 harmacologic interventions are used to treat neuropsychiatric symptoms in persons with dementia.

172 brain ALA may be involved in generating the neuropsychiatric symptoms in porphyrias and that systemi

173 vide new insight into the molecular basis of neuropsychiatric symptoms in pre-HD and suggest new ther

174 mer's disease, contributing to cognitive and neuropsychiatric symptoms in some patients.

175 S-CoV-2) produces an array of neurologic and neuropsychiatric symptoms in the acute and post-acute ph

176 microstructural alterations associated with neuropsychiatric symptoms in the chronic phase of mTBI.

177 Study of neuropsychiatric symptoms in the context of dementia may

178 The neuropsychiatric symptoms in the former group included p

179 43% of MCI participants (n = 138) exhibited neuropsychiatric symptoms in the previous month (29% rat

180 alternatives for the long-term treatment of neuropsychiatric symptoms in these patients.

181 o network malfunction leading to progressive neuropsychiatric symptoms in TSC.

182 Among all 24 neuropsychiatric symptoms included in the Harvard Lesion

183 iated with acute and postacute cognitive and neuropsychiatric symptoms including impaired memory, con

184 Abrupt onset of severe neuropsychiatric symptoms including obsessive-compulsive

185 e (AD), many patients also develop prominent neuropsychiatric symptoms, including anxiety and depress

186 ry interventions and interventions to reduce neuropsychiatric symptoms, including depression, that in

187 imer's disease (AD) is associated with other neuropsychiatric symptoms, including severe depression.

188 Most behavioral and neuropsychiatric symptoms increased in the early-interme

189 thermore, a post-viral syndrome dominated by neuropsychiatric symptoms is common, and is seemingly un

190 ology and cognitive deficits on longitudinal neuropsychiatric symptoms is unclear, especially in earl

191 nts is associated with the severity of these neuropsychiatric symptoms is unknown.

192 e disorder (OCD) cases exhibiting additional neuropsychiatric symptoms, it was proposed that neuroinf

193 elusions loaded together, with the remaining neuropsychiatric symptoms loading with the core behaviou

194 The detection of early neuropsychiatric symptoms might be a marker for dementia

195 depressed (n = 44), nondepressed with other neuropsychiatric symptoms (n = 93), and no-symptom (NOSY

196 Main outcomes were neuropsychiatric symptoms (Neuropsychiatric Inventory [N

197 ne patients with SLE with a history of overt neuropsychiatric symptoms (neuropsychiatric SLE [NPSLE])

198 [NPSLE]), 22 patients with SLE without overt neuropsychiatric symptoms (non-NPSLE), and 25 healthy co

199 NPSLE), 22 SLE patients without a history of neuropsychiatric symptoms (non-NPSLE), and 25 healthy co

200 outcomes were: 12 weeks CMAI; 6 and 12 weeks Neuropsychiatric symptoms (NPI), Clinical Global Impress

201 Apathy is a common neuropsychiatric symptom (NPS) in Alzheimer's disease (A

202 Neuropsychiatric symptoms (NPS) are common in hereditary

203 the lack of awareness of memory decline, and Neuropsychiatric Symptoms (NPS) are prevalent and debili

204 Whether or not neuropsychiatric symptoms (NPS) in advance of dementia a

205 ted dementias (ADRD) pathologies with common neuropsychiatric symptoms (NPS) may have implications fo

206 MRI, is associated with stage of AD and with neuropsychiatric symptoms (NPS), independent of cortical

207 Almost all AD patients suffer from neuropsychiatric symptoms (NPS), the emergence of which

208 Thirty-one SLE patients with a history of neuropsychiatric symptoms (NPSLE), 22 SLE patients witho

209 n the pathogenesis of SLE and its associated neuropsychiatric symptoms (NPSLE).

210 Understanding the heterogeneity of neuropsychiatric symptoms (NPSs) and associated brain ab

211 Neuropsychiatric symptoms (NPSs) in Alzheimer's disease

212 x behaviours as a 'lesion-based' approach to neuropsychiatric symptoms observed across diagnostic cat

213 blood-brain barrier (BBB) may contribute to neuropsychiatric symptoms observed in Long COVID (LC).

214 responsible for the transient and permanent neuropsychiatric symptoms observed in patients with SLE.

215 Neuropsychiatric symptoms occur in mutation carriers at

216 Neuropsychiatric symptoms occur in the majority of perso

217 Apathy was the key neuropsychiatric symptom occurring most often in advance

218 nestic MCI, suggesting that anxiety may be a neuropsychiatric symptom of Alzheimer's disease (AD) pat

219 Neuropsychiatric symptoms of Alzheimer's disease seem to

220 cal manifestations was high.Neurological and neuropsychiatric symptoms of COVID-19 in the pandemic's

221 Neuropsychiatric symptoms of dementia (NPS) are a group

222 The behavioral and neuropsychiatric symptoms of dementia and Alzheimer's di

223 have been implicated in the pathogenesis of neuropsychiatric symptoms of dementia but the functional

224 Use of atypical antipsychotics for neuropsychiatric symptoms of dementia increased markedly

225 vatives as alternative agents to address the neuropsychiatric symptoms of dementia may carry associat

226 wing new antipsychotic medication starts for neuropsychiatric symptoms of dementia were compared with

227 Many neuropsychiatric symptoms of fragile X syndrome (FXS) ar

228 stimulation in psychiatric disorders and the neuropsychiatric symptoms of Parkinson's disease, these

229 delineate a molecular pathomechanism for the neuropsychiatric symptoms of patients carrying intersect

230 macological intervention is unsuccessful and neuropsychiatric symptoms or associated behaviors cause

231 remains difficult to accurately elucidate if neuropsychiatric symptoms or conditions are indicators o

232 The presence of neuropsychiatric symptoms or lower serum folate levels p

233 with Alzheimer disease (AD) often experience neuropsychiatric symptoms, particularly anxious-depressi

234 izophrenia (SCZ) suggest that in addition to neuropsychiatric symptoms, patients with SCZ also show v

235 support the growing consensus that distinct neuropsychiatric symptom patterns are associated with di

236 The authors sought to determine which neuropsychiatric symptoms predict relapse.

237 atients with COVID-19 and prominent subacute neuropsychiatric symptoms, ranging from severe anxiety t

238 isk' patients be identified prior to DBS; do neuropsychiatric symptoms relate to the distribution of

239 h hepatitis C virus infection as well as the neuropsychiatric symptoms related to hepatitis C and IFN

240 lder adults, suggesting that loneliness is a neuropsychiatric symptom relevant to preclinical AD.

241 Increases in pain were associated with worse neuropsychiatric symptom scores within all groups.

242 otor and vocal tics and certain of the other neuropsychiatric symptoms seen in Tourette syndrome are

243 ents with encephalopathy plus one or more of neuropsychiatric symptoms, seizures, movement disorder o

244 haviour rating of executive dysfunction, and neuropsychiatric symptom severity) was higher in those w

245 risk factors (BMI, education, hypertension, neuropsychiatric symptom severity), global amyloid, tau

246 y mass index (BMI), hypertension, education, neuropsychiatric symptom severity, and demographic infor

247 Our results showed that neuropsychiatric symptoms show strong links to both MHPG

248 Many FTLD-related clinical and neuropsychiatric symptoms such as aggressive and compuls

249 Neuropsychiatric symptoms such as agitation and delusion

250 ions as a promising approach to the study of neuropsychiatric symptoms such as anxiety in cognitively

251 Loneliness is a neuropsychiatric symptom that has been associated with c

252 An increasing appreciation for neuropsychiatric symptoms that arise from cerebellar dys

253 Alzheimer's disease (AD) patients exhibit neuropsychiatric symptoms that extend beyond classical c

254 Post-Concussion Syndrome, a constellation of neuropsychiatric symptoms that includes depression, anxi

255 It occurs with severe neuropsychiatric symptoms that often improve with immuno

256 ion effect or the pathophysiology underlying neuropsychiatric symptoms that prompt antipsychotic use.

257 y, up to 75% of patients with SLE experience neuropsychiatric symptoms that range from anxiety, depre

258 n participants post-COVID-19 with persistent neuropsychiatric symptoms, the lower-than-normal tNAA an

259 oup), insomnia (seven [8%] vs one [2%]), and neuropsychiatric symptoms (three [4%] vs none [0%]).

260 are, did not significantly improve patients' neuropsychiatric symptoms through 24 months.

261 method to localize clinical, cognitive, and neuropsychiatric symptoms to brain networks, providing i

262 re assessed the frequency and severity of 14 neuropsychiatric symptoms: visual, auditory, and tactile

263 Severity of delusions and other neuropsychiatric symptoms was assessed by using a semist

264 The course of neuropsychiatric symptoms was prolonged and often associ

265 ould increase the risk of aggression-related neuropsychiatric symptoms, we used the Harvard Lesion Re

266 Sixty individuals with SLE and no overt neuropsychiatric symptoms were administered ANAM to dete

267 Behavioral and neuropsychiatric symptoms were assessed across disease d

268 the Katz Activity of Daily Living index, and neuropsychiatric symptoms were assessed through The Neur

269 n Cognitive Decline in the Elderly (IQCODE); neuropsychiatric symptoms were evaluated using the Neuro

270 Neuropsychiatric symptoms were more frequent but transie

271 Neuropsychiatric symptoms were rated using the Beck Depr

272 ies reporting prevalences of neurological or neuropsychiatric symptoms were synthesised into meta-ana

273 Alongside behavioral symptoms, neuropsychiatric symptoms were very frequently reported

274 patients with MS may also show co-occurring neuropsychiatric symptoms with disease progression.

275 trum disorder (ASD) encompasses wide-ranging neuropsychiatric symptoms with unclear etiology.

276 ients presenting with tinnitus commonly have neuropsychiatric symptoms with which physicians need to